Biocon Biologics Signs Settlement and License Agreement to Commercialize Biosimilar Aflibercept Worldwide
BENGALURU, India, December 17, 2025: Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE: 532523, NSE: BIOCON), announced a new settlement and license agreement with Regeneron and Bayer for biosimilar Aflibercept (40mg/ml) in Europe and the rest of the world, which follows an earlier settlement covering the United…